Philadelphia-based AI drug discovery company BioPhy has raised USD 4.5 million in seed funding led by Metrodora Ventures, with participation from Audere Capital and individual investors, including Jeff Marrazzo, the co-founder of Spark Therapeutics.
The funds will be used to advance BioPhy's AI platform further, expand the company’s R&D operations, and expand its business reach.
BioPhy leverages its patent-pending predictive AI engine BiologicAI to identify, develop, and test drugs and also aids in the improvement of clinical trial outcomes, decreasing trial failure rates and speeding up drug development. BioPhyRx, a part of BioPhy, is a GenAI solution designed to create a centralized area to access scientific and regulatory resources.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.